Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC022 CAR-T for Relapsed/Refractory B-ALL
NCT03825731Phase 1Unknown
- Sponsor
- Lu Daopei Hospital
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC022 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Lu Daopei Hospital. Primary endpoints: Number of Patients with Dose Limiting Toxicity at 12 weeks, Incidence of adverse events at 12 weeks and 1 more. Status: unknown.
02
Drugs
GC022
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03825731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03825731.